Aptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/24/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY

6. BABA
7. AVGO
8. SPCX
9. JMKE
10. BJ

Get Alerts APTX Hot Sheet

Price: $0.06 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held November 29, 2021 through December 2, 2021.

The pre-recorded fireside chat will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com beginning on Monday, November 22, 2021 at 10 a.m. ET and will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx.

Source: Aptinyx Inc.